Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.

Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R.

Expert Rev Gastroenterol Hepatol. 2017;11(1):85-93

Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency.

Vallejo-Torres L, Castilla I, Couce ML, Pérez-Cerdá C, Martín-Hernández E, Pineda M, Campistol J, Arrospide A, Morris S, Serrano-Aguilar P.

Pediatrics. 2015 Aug;136(2):e424-32.

Hip fracture incidence in Spain.

Etxebarria-Foronda I.

Med. Clin. 2015; 145: 482-484. FI: 1.417 (Q2).

Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización.

Etxebarria-Foronda I, Caeiro-Rey JR, Larrainzar-Garijo R, Vaquero-Cervino E, Roca-Ruiz L, Mesa-Ramos M, Merino Pérez J, Carpintero-Benitez P, Fernández Cebrián A, Gil-Garay E.

Rev Esp Cir Ortop Traumatol. 2015; 59: 373-393. FI: 0.000 (Q0).

An atypical fracture in male patient with osteogenesis imperfecta.

Etxebarria-Foronda I, Carpintero P.

Clin Cases Miner Bone Metab. 2015; 12: 278-281. FI: 0.000 (Q0).

Projecting Burden of Dementia in Spain, 2010-2050: Impact of Modifying Risk Factors.

Soto-Gordoa M, Arrospide A, Moreno-Izco F, Martinez-Lage P, Castilla I, Mar J.

J. Alzheimers Dis. 2015; 48: 721-730. FI: 4.151 (Q1).

Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.

San Miguel R, Gimeno-Ballester V, Blazquez A, Mar J.

Gut. 2015; 64: 1277-122. FI: 14.660 (Q1).

Cost of Breast Cancer Treatment by Clinical Stage in the Basque Country, Spain.

Arrospide A, Soto-Gordoa M, Acaiturri T, Lopez-Vivanco G, Abecia LC, Mar J.

Rev. Esp. Salud Publica. 2015; 89: 93-97. FI: 0.600 (Q4).

Regional variability in changes in the incidence of hip fracture in the Spanish population (2000-2012).

Etxebarria-Foronda I, Arrospide A, Soto-Gordoa M, Caeiro JR, Abecia LC, Mar J.

Osteoporosis Int. 2015; 26: 1491-1497. FI: 4.169 (Q2).

CONOCES Investigators Grp. Outcomes measured by mortality rates, quality of life and degree of autonomy in the first year in stroke units in Spain.

Mar J, Masjuan J, Oliva-Moreno J, Gonzalez-Rojas N, Becerra V, Casado MA, Torres C, Yebenes M, Quintana M, Alvarez-Sabin J.

Health Qual. Life Outcomes. 2015; 13. FI: 2.120 (Q2).

Fitting the epidemiology and neuropathology of the early stages of Alzheimer’s disease to prevent dementia.

Mar J, Soto-Gordoa M, Arrospide A, Moreno-Izco F, Martinez-Lage P.

Alzheimers Res. Ther. 2015; 7. FI: 3.979 (Q1).

Cost-analysis of viscosupplementation treatment with hyaluronic acid in candidate knee replacement patients with osteoarthritis.

Mar J, Romero-Jurado M, Arrospide A, Enrique-Fidalgo A, Soler-Lopez B.

Rev Esp Cir Ortop Traumatol. 2013; 57 (1): 6-14. FI: 0.000 (Q0).

Is the incidence of hip fractures becoming lower?

Etxebarria-Foronda I, Mar J.

Reumatol Clin. 2013; 9 (2): 131. FI: 0.000 (Q0).

Cost-effectiveness of protease based regimens for chronic hepatites C: a systematic review of published literature.

San Miguel R, Gimeno-Ballester V, Mar J.

Expert Ver Pharmacoecon Outcomes Res. 2014; 14 (3): 387-402. FI: 1.870 (Q2).